Reitz M, Witzke G, Egbring R, Gutjahr P
Klin Wochenschr. 1984 Dec 17;62(24):1165-9. doi: 10.1007/BF01712183.
The thrombocyte count, the factor XIII (F XIII) activity, the concentration of fibrinogen (F I), prothrombin (F II), fibronectin (CIG), albumin and the proteinase inhibitors antithrombin III (AT III), alpha 2-macroglobulin (A2M), alpha 1-antitrypsin (A1A) and Cl-esterase inactivator (Cl-INA) were determined in ten children with acute lymphoblastic leukaemia (ALL). Changes due to the disease and to therapy were observed. Before the start of treatment the patients had thrombocytopenia secondary to the disease, and the proteinase inhibitors--especially Cl-INA and A1A--were raised. During the induction phase the thrombocyte count rose but there was also a marked increase in the concentration of F II and CIG. During the consolidation phase there was a general fall in protein concentration under L-asparaginase medication. The cause was attributed to a disorder of protein synthesis. The concentration of the factors studied rose again during maintenance therapy.
对10例急性淋巴细胞白血病（ALL）患儿进行了血小板计数、因子 XIII（F XIII）活性、纤维蛋白原（F I）、凝血酶原（F II）、纤连蛋白（CIG）、白蛋白以及蛋白酶抑制剂抗凝血酶 III（AT III）、α2-巨球蛋白（A2M）、α1-抗胰蛋白酶（A1A）和Cl酯酶灭活剂（Cl-INA）的检测。观察了疾病及治疗引起的变化。治疗开始前，患者因疾病继发血小板减少，蛋白酶抑制剂——尤其是Cl-INA和A1A——升高。诱导期血小板计数上升，但F II和CIG浓度也显著增加。巩固期在使用L-天冬酰胺酶治疗期间蛋白质浓度普遍下降。原因归因于蛋白质合成紊乱。维持治疗期间所研究因子的浓度再次升高。
